Reversing Liver Damage via the Gut
An experimental drug, DT-109, has successfully reversed metabolic dysfunction-associated steatohepatitis (MASH) in animal models. By restoring gut barrier integrity, the glycine-based tripeptide interrupts the gut-liver axis, blocking the microbial products that trigger liver inflammation. The study, published in The Journal of Clinical Investigation, offers a new strategy for treating a condition that affects roughly 7% of the global population.
Bacteria and the Breakdown of Liver Health
MASH is a progressive, dangerous form of fatty liver disease. If left unchecked, it leads to cirrhosis, liver failure, and cancer. Researchers at Michigan Medicine found that the disease is often fueled by an overgrowth of Clostridium perfringens in the gut. This bacterium produces ammonia, a byproduct that erodes the intestinal epithelial barrier. Once that barrier fails, microbial toxins flood the bloodstream, reaching the liver to activate inflammatory responses, including CD8+ T cells.
Repairing the Intestinal Barrier
DT-109 targets the source of the inflammation by modulating the microbiota and fortifying the intestinal lining. “We see clear evidence that DT-109 protects the gut epithelial barrier, reducing the systemic influx of harmful microbial products that are thought to contribute to MASH development and progression,” said Eugene Chen, M.D., Ph.D., senior author of the study and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at the University of Michigan Medical School.
Efficacy in Preclinical Models
The research team tested the compound in mice and nonhuman primates. Because nonhuman primates share similar gut microbiota and liver biology with humans, they served as a critical test for the drug. In these trials, DT-109 significantly reduced both liver inflammation and the overall severity of MASH.
“DT-109 connects microbiota modulation with liver protection by restoring gut barrier integrity and limiting the systemic translocation of ammonia and other pro-inflammatory microbial products within the gut-liver axis,” explained Jifeng Zhang, Ph.D., co-author and research professor of cardiovascular medicine at U-M Medical School.
Broad Therapeutic Potential
The scope of DT-109 may extend well beyond the liver. Previous laboratory findings suggest the compound can inhibit atherosclerotic plaque formation and prevent vascular calcification, pointing toward a dual benefit for cardiovascular and liver health. Because a compromised gut barrier is a hallmark of many digestive disorders, scientists believe the drug could eventually be explored as a treatment for inflammatory bowel disease (IBD).
Commercial Development and Next Steps
The study was conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Several authors—Ying Zhao, Oren Rom, Jifeng Zhang, and Y. Eugene Chen—are listed as inventors on a patent application for the tripeptide. The University of Michigan has licensed the compound to Diapin Therapeutics, a company in which Chen and the university hold an ownership interest. Diapin Therapeutics provided the DT-109 used in the study. While animal results are promising, the team must now undergo the rigorous safety and efficacy testing required to move toward human clinical trials.
Related reading